Direct inflammasome inhibition attenuated COVID-19 severity in a preclinical model, but potent forms of such inhibitors are not yet in clinical use, which leaves the option of inhibiting downstream cytokines IL-1β and IL-18 [56, 57]. Here, IL1B is linked to COVID-19.